Functional characterization of the 1,5-benzodiazepine clobazam and its major active metabolite n-desmethylclobazam at human GABAA receptors expressed in xenopus laevis oocytes

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Hammer, Harriet ^a   Ebert, Bjarke ^b   Jensen, Henrik Sindal ^b   Jensen, Anders A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1BETA2GAMMA2S; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2BETA2GAMMA2S; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3BETA2GAMMA2S; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5BETA2GAMMA2S; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA6BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA6BETA2DELTA; CLOBAZAM; NORCLOBAZAM; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; N-DESMETHYLCLOBAZAM;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; EC50; ELECTROPHYSIOLOGY; FEMALE; HUMAN; IN VITRO STUDY; NONHUMAN; OOCYTE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TWO ELECTRODE VOLTAGE CLAMP; VOLTAGE CLAMP TECHNIQUE; XENOPUS LAEVIS; ANIMAL; GENE EXPRESSION; GENETICS; METABOLISM;

XENOPUS LAEVIS;

ANIMALS; BENZODIAZEPINES; GABA-A RECEPTOR AGONISTS; GABA-A RECEPTOR ANTAGONISTS; GENE EXPRESSION; HUMANS; OOCYTES; RECEPTORS, GABA-A; XENOPUS LAEVIS;

EID: 84925728297     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120239     Document Type: Article

References (77)

1. Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABAB receptors. Physiol Rev 2004; 84: 835-867. PMID: 15269338
2. Olsen RW, Sieghart W. GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009; 56: 141-148. doi: 10.1016/j.neuropharm.2008.07.045 PMID: 18760291
3. Lynch JW. Native glycine receptor subtypes and their physiological roles. Neuropharmacology 2009; 56: 303-309. doi: 10.1016/j.neuropharm.2008.07.034 PMID: 18721822
4. Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT3 receptor-the relationship between structure and function. Neuropharmacology 2009; 56: 273-284. doi: 10.1016/j.neuropharm.2008.08.003 PMID: 18761359
5. Jensen AA, Frølund B, Liljefors T, Krogsgaard-Larsen P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem 2005; 48: 4705-4745. PMID: 16033252
6. Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacological reviews 2008; 60: 243-260. doi: 10.1124/pr.108.00505 PMID: 18790874
7. Whiting PJ. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today 2003; 8: 445-450. PMID: 12801796
8. Baumann SW, Baur R, Sigel E. Forced subunit assembly in α1β2γ2 GABAA receptors. Insight into the absolute arrangement. J Biol Chem 2002; 277: 46020-46025. PMID: 12324466
9. Baur R, Minier F, Sigel E. A GABAA receptor of defined subunit composition and positioning: concatenation of five subunits. FEBS Lett 2006; 580: 1616-1620. PMID: 16494876
10. Brickley SG, Mody I. Extrasynaptic GABAA receptors: their function in the CNS and implications for disease. Neuron 2012; 73: 23-34. doi: 10.1016/j.neuron.2011.12.012 PMID: 22243744
11. Belelli D, Harrison NL, Maguire J, Macdonald RL, Walker MC, Cope DW. Extrasynaptic GABAA receptors: form, pharmacology, and function. J Neurosci 2009; 29: 12757-12763. doi: 10.1523/JNEUROSCI.3340-09.2009 PMID: 19828786
12. Atack JR. GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem 2011; 11: 1176-1202. PMID: 21050172
13. Atack JR. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement. Curr Top Med Chem 2011; 11: 1203-1214. PMID: 21050171
14. Sieghart W. Allosteric modulation of GABAA receptors via multiple drug-binding sites. Adv Pharmacol in press.
15. Ebert B, Wafford KA, Deacon S. Treating insomnia: Current and investigational pharmacological approaches. Pharmacol Ther 2006; 112: 612-629. PMID: 16876255
16. Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 2011; 10: 685-697. doi: 10.1038/nrd3502 PMID: 21799515
17. Sigel E, Lüscher BP. A closer look at the high affinity benzodiazepine binding site on GABAA receptors. Curr Top Med Chem 2011; 11: 241-246. PMID: 21189125
18. Walters RJ, Hadley SH, Morris KD, Amin J. Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. Nat Neurosci 2000; 3: 1274-1281. PMID: 11100148
19. Baur R, Tan KR, Lüscher BP, Gonthier A, Goeldner M, Sigel E. Covalent modification of GABAA receptor isoforms by a diazepam analogue provides evidence for a novel benzodiazepine binding site that prevents modulation by these drugs. Journal of neurochemistry 2008; 106: 2353-2363. doi: 10.1111/j.1471-4159.2008.05574.x PMID: 18643789
20. Ramerstorfer J, Furtmuller R, Sarto-Jackson I, Varagic Z, SieghartW, Ernst M. The GABAA receptor α +β- interface: a novel target for subtype selective drugs. J Neurosci 2011; 31: 870-877. doi: 10.1523/JNEUROSCI.5012-10.2011 PMID: 21248110
21. Varagic Z, Ramerstorfer J, Huang S, Rallapalli S, Sarto-Jackson I, Cook J, et al. Subtype selectivity of α+β- site ligands of GABAA receptors: identification of the first highly specific positive modulators at α6β2/3γ2 receptors. Br J Pharmacol 2013; 169: 384-399. doi: 10.1111/bph.12153 PMID: 23472935
22. Mirheydari P, Ramerstorfer J, Varagic Z, Scholze P, Wimmer L, Mihovilovic MM, et al. Unexpected properties of δ-containing GABAA receptors in response to ligands interacting with the α+ β- site. Neurochemical research 2014; 39: 1057-1067. doi: 10.1007/s11064-013-1156-3 PMID: 24072672
23. Wallner M, Hanchar HJ, Olsen RW. Alcohol selectivity of β3-containing GABAA receptors: evidence for a unique extracellular alcohol/imidazobenzodiazepine Ro15-4513 binding site at the α+β- subunit interface in αβ3δ GABAA receptors. Neurochemical research 2014; 39: 1118-1126. doi: 10.1007/s11064-014-1243-0 PMID: 24500446
24. Engin E, Liu J, Rudolph U. α2-containing GABAA receptors: a target for the development of novel treatment strategies for CNS disorders. Pharmacol Ther 2012; 136: 142-152. doi: 10.1016/j.pharmthera.2012.08.006 PMID: 22921455
25. Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, et al. Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994; 18: 355-372. PMID: 7984354
26. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype. Nat Neurosci 2000; 3: 587-592. PMID: 10816315
27. Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 915-920. PMID: 15644443
28. Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acidA receptor subtypes. Nature 1999; 401: 796-800. PMID: 10548105
29. Fradley RL, Guscott MR, Bull S, Hallett DJ, Goodacre SC, Wafford KA, et al. Differential contribution of GABAA receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. J Psychopharmacol 2007; 21: 384-391. PMID: 17092983
30. Cramer JA, Sapin C, Francois C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurol Scand 2013; 128: 91-99. doi: 10.1111/ane.12086 PMID: 23410109
31. Leahy JT, Chu-Shore CJ, Fisher JL. Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome. Neuropsychiatr Dis Treat 2011; 7: 673-681. doi: 10.2147/NDT.S20173 PMID: 22128252
32. Ng YT, Collins SD. Clobazam. Neurotherapeutics 2007; 4: 138-144. PMID: 17199029
33. van der Meyden CH, Bartel PR, Sommers DK, Blom M, Pretorius LC. Effects of clobazam and clonazepam on saccadic eye movements and other parameters of psychomotor performance. Eur J Clin Pharmacol 1989; 37: 365-369. PMID: 2689183
34. Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L. Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol 1990; 29: 169-177. PMID: 2106335
35. Steru L, Chermat R, Millet B, Mico JA, Simon P. Comparative study in mice of ten 1,4-benzodiazepines and of clobazam: anticonvulsant, anxiolytic, sedative, and myorelaxant effects. Epilepsia 1986; 27 Suppl 1: S14-17. PMID: 2874986
36. Miura Y, Amano S, Torii R, Ihara N. Clobazam shows a different antiepileptic action profile from clonazepam and zonisamide in Ihara epileptic rats. Epilepsy research 2002; 49: 189-202. PMID: 12076840
37. Tolbert D, Bekersky I. Pharmacokinetics of N-desmethylclobazam, the active and primary metabolite of Clobazam. 66th Annual Meeting of the American Epilepsy Society. San Diego, CA. Epilepsy Currents 2013;13: Suppl 1. Abstract #2.226.
38. Haigh JR, Pullar T, Gent JP, Dailley C, Feely M. N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy? Br J Clin Pharmacol 1987; 23: 213-218. PMID: 3828198
39. Kinoshita M, Ikeda A, Begum T, Terada K, Shibasaki H. Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB. J Neurol Sci 2007; 263: 44-48. PMID: 17588610
40. Sankar R. GABAA receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs 2012; 26: 229-244. doi: 10.2165/11599020-000000000-00000 PMID: 22145708
41. Jensen HS, Nichol K, Lee D, Ebert B. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α2- versus α1-GABAA-receptor complexes. PLoS One 2014; 9: e88456. doi: 10.1371/journal.pone.0088456 PMID: 24533090
42. Jensen AA, Bergmann ML, Sander T, Balle T. Ginkgolide X is a potent antagonist of anionic Cys-loop receptors with a unique selectivity profile at glycine receptors. J Biol Chem 2010; 285: 10141-10153. doi: 10.1074/jbc.M109.079319 PMID: 20106969
43. Hoestgaard-Jensen K, Dalby NO, Krall J, Hammer H, Krogsgaard-Larsen P, Frølund B, et al. Probing α4βδ GABAA receptor heterogeneity: differential regional effects of a functionally selective α4β1δ/α4β3δ receptor agonist on tonic and phasic inhibition in rat brain. J Neurosci 2014; 34: 16256-16272 doi: 10.1523/JNEUROSCI.1495-14.2014 PMID: 25471566
44. Storustovu S, Ebert B. Gaboxadol: in vitro interaction studies with benzodiazepines and ethanol suggest functional selectivity. European journal of pharmacology 2003; 467: 49-56. PMID: 12706454
45. Storustovu SI, Ebert B. Pharmacological characterization of agonists at δ-containing GABAA receptors: Functional selectivity for extrasynaptic receptors is dependent on the absence of γ2. J Pharmacol Exp Ther 2006; 316: 1351-1359. PMID: 16272218
46. Karim N, Wellendorph P, Absalom N, Johnston GA, Hanrahan JR, Chebib M. Potency of GABA at human recombinant GABAA receptors expressed in Xenopus oocytes: a mini review. Amino Acids 2013; 44: 1139-1149. doi: 10.1007/s00726-012-1456-y PMID: 23385381
47. Wafford KA, van Niel MB, Mab QP, Horridge E, Herd MB, Peden DR, et al. Novel compounds selectively enhance δ subunit containing GABAA receptors and increase tonic currents in thalamus. Neuropharmacology 2009; 56: 182-189. doi: 10.1016/j.neuropharm.2008.08.004 PMID: 18762200
48. Karim N, Wellendorph P, Absalom N, Bang LH, Jensen ML, Hansen MM, et al. Low nanomolar GABA effects at extrasynaptic α4β1/β3δ GABAA receptor subtypes indicate a different binding mode for GABA at these receptors. Biochem Pharmacol 2012; 84: 549-557. doi: 10.1016/j.bcp.2012.05.017 PMID: 22658986
49. You H, Dunn SM. Identification of a domain in the δsubunit (S238-V264) of the α4β3δ GABAA receptor that confers high agonist sensitivity. Journal of neurochemistry 2007; 103: 1092-1101. PMID: 17711419
50. Krishek BJ, Moss SJ, Smart TG. Interaction of H+ and Zn2+ on recombinant and native rat neuronal GABAA receptors. The Journal of physiology 1998;507 (Pt 3:): 639-652.
51. Hoestgaard-Jensen K, O'Connor RM, Dalby NO, Simonsen C, Finger BC, Golubeva A, et al. The orthosteric GABAA receptor ligand 5-(4-piperidyl)-3-isothiazolol (Thio-4-PIOL) displays distinctly different functional properties at synaptic and extrasynaptic receptors. Br J Pharmacol 2013; 170: 919-932. doi: 10.1111/bph.12340 PMID: 23957253
52. Petroski RE, Pomeroy JE, Das R, Bowman H, Yang W, Chen AP, et al. Indiplon is a high-affinity positive allosteric modulator with selectivity for α1 subunit-containing GABAA receptors. The Journal of pharmacology and experimental therapeutics 2006; 317: 369-377. PMID: 16399882
53. Smart TG, Moss SJ, Xie X, Huganir RL. GABAA receptors are differentially sensitive to zinc: dependence on subunit composition. Br J Pharmacol 1991; 103: 1837-1839. PMID: 1655141
54. Hosie AM, Dunne EL, Harvey RJ, Smart TG. Zinc-mediated inhibition of GABAA receptors: discrete binding sites underlie subtype specificity. Nat Neurosci 2003; 6: 362-369. PMID: 12640458
55. Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S. Pharmacological properties of GABAA receptors containing γ1 subunits. Mol Pharmacol 2006; 69: 640-649. PMID: 16272224
56. Hevers W, Lüddens H. The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Molecular neurobiology 1998; 18: 35-86. PMID: 9824848
57. Sieghart W. Structure and pharmacology of γ-aminobutyric acidA receptor subtypes. Pharmacol Rev 1995; 47: 181-234. PMID: 7568326
58. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G. GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 2000; 101: 815-850. PMID: 11113332
59. Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 1992; 12: 1040-1062. PMID: 1312131
60. Fisher JL. Interactions between modulators of the GABAA receptor: Stiripentol and benzodiazepines. European journal of pharmacology 2011; 654: 160-165. doi: 10.1016/j.ejphar.2010.12.037 PMID: 21237147
61. Bowser DN, Wagner DA, Czajkowski C, Cromer BA, Parker MW, Wallace RH, et al. Altered kinetics and benzodiazepine sensitivity of a GABAA receptor subunit mutation [γ2(R43Q)] found in human epilepsy. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 15170-15175. PMID: 12415111
62. Buhr A, Baur R, Malherbe P, Sigel E. Point mutations of the α1β2γ2 gamma-aminobutyric acidA receptor affecting modulation of the channel by ligands of the benzodiazepine binding site. Mol Pharmacol 1996; 49: 1080-1084. PMID: 8649346
63. Rabe H, Kronbach C, Rundfeldt C, Luddens H. The novel anxiolytic ELB139 displays selectivity to recombinant GABAA receptors different from diazepam. Neuropharmacology 2007; 52: 796-801. PMID: 17087982
64. Morlock EV, Czajkowski C. Different residues in the GABAA receptor benzodiazepine binding pocket mediate benzodiazepine efficacy and binding. Mol Pharmacol 2011; 80: 14-22. doi: 10.1124/mol.110.069542 PMID: 21447642
65. Rahman M, Lindblad C, Johansson IM, Backstrom T, Wang MD. Neurosteroid modulation of recombinant rat α5β2γ2L and α1β2γ2L GABAA receptors in Xenopus oocyte. European journal of pharmacology 2006; 547: 37-44. PMID: 16934248
66. Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes. European journal of pharmacology 2002; 451: 103-110. PMID: 12231378
67. Feng HJ, Bianchi MT, Macdonald RL. Pentobarbital differentially modulates α1β3δ and α1β3γ2L GABAA receptor currents. Mol Pharmacol 2004; 66: 988-1003. PMID: 15247320
68. Pistis M, Belelli D, Peters JA, Lambert JJ. The interaction of general anaesthetics with recombinant GABAA and glycine receptors expressed in Xenopus laevis oocytes: a comparative study. Br J Pharmacol 1997; 122: 1707-1719. PMID: 9422818
69. Wooltorton JR, Moss SJ, Smart TG. Pharmacological and physiological characterization of murine homomeric β3 GABAA receptors. Eur J Neurosci 1997; 9: 2225-2235. PMID: 9464918
70. Feng HJ, Macdonald RL. Barbiturates require the N terminus and first transmembrane domain of the δ subunit for enhancement of α1β3δ GABAA receptor currents. J Biol Chem 2010; 285: 23614-23621. doi: 10.1074/jbc.M110.122564 PMID: 20525684
71. Halliwell RF, Thomas P, Patten D, James CH, Martinez-Torres A, Miledi R, et al. Subunit-selective modulation of GABAA receptors by the non-steroidal anti-inflammatory agent, mefenamic acid. Eur J Neurosci 1999; 11: 2897-2905. PMID: 10457186
72. Hill-Venning C, Belelli D, Peters JA, Lambert JJ. Subunit-dependent interaction of the general anaesthetic etomidate with the γ-aminobutyric acid type A receptor. Br J Pharmacol 1997; 120: 749-756. PMID: 9138677
73. Sigel E, Steinmann ME. Structure, function, and modulation of GABAA receptors. J Biol Chem 2012; 287: 40224-40231. doi: 10.1074/jbc.R112.386664 PMID: 23038269
74. Olsen JA, Kastrup JS, Peters D, Gajhede M, Balle T, Ahring PK. Two distinct allosteric binding sites at α4β2 nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique insights to binding activity-associated linkage at Cys-loop receptors. J Biol Chem 2013; 288: 35997-36006. doi: 10.1074/jbc.M113.498618 PMID: 24169695
75. Feng HJ, Macdonald RL. Multiple actions of propofol on αβγ and αβδ GABAA receptors. Mol Pharmacol 2004; 66: 1517-1524. PMID: 15331770
76. Young GT, Zwart R, Walker AS, Sher E, Millar NS. Potentiation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 2008; 105: 14686-14691. doi: 10.1073/pnas.0804372105 PMID: 18791069
77. Wu TY, Smith CM, Sine SM, Levandoski MM. Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine α3β2 receptors. Mol Pharmacol 2008; 74: 466-475. doi: 10.1124/mol.107.044388 PMID: 18458055